Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Concord Biotech Limited (CONCORDBIO.NS)
Ahmedabad, GJ, IN
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.46% | -10.69% | -8.00% | -13.93% | -25.89% | -21.92% | -42.26% | +11.43% | +11.43% | +11.43% | +11.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-12.1% Q1'26: -24.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-30.2% Q1'26: -37.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+18.3% ★ Q1'26: +29.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+27.8% ★ Q1'26: +30.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+13.8% ★ Q1'26: +19.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.6% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.01× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 4 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
10.17B
est: 10.38B (-2.0%)
|
12.00B
est: 11.58B (+3.6%)
|
11.57B
11.04B – 12.31B
-0.1% YoY
|
14.25B
13.78B – 15.08B
+23.2% YoY
|
17.32B
16.36B – 19.43B
+21.5% YoY
|
| EBITDA |
4.39B
est: 4.17B (+5.1%)
|
5.13B
est: 4.65B (+10.2%)
|
4.65B
4.44B – 4.95B
-0.1% YoY
|
5.73B
5.54B – 6.06B
+23.2% YoY
|
6.96B
6.58B – 7.81B
+21.5% YoY
|
| EBIT |
3.87B
est: 3.56B (+8.7%)
|
4.60B
est: 3.97B (+15.9%)
|
3.97B
3.79B – 4.22B
-0.1% YoY
|
4.88B
4.72B – 5.17B
+23.2% YoY
|
5.94B
5.61B – 6.66B
+21.5% YoY
|
| Net Income |
3.08B
est: 3.13B (-1.6%)
|
3.72B
est: 3.56B (+4.4%)
|
3.00B
2.62B – 3.38B
-15.7% YoY
|
4.10B
3.37B – 4.42B
+36.5% YoY
|
5.28B
4.14B – 5.75B
+28.8% YoY
|
| SGA |
1.23B
est: 1.33B (-7.6%)
|
1.39B
est: 1.48B (-6.4%)
|
1.48B
1.42B – 1.58B
-0.1% YoY
|
1.83B
1.77B – 1.93B
+23.2% YoY
|
2.22B
2.10B – 2.49B
+21.5% YoY
|
| EPS |
29.45
est: 29.94 (-1.6%)
|
35.52
est: 33.43 (+6.2%)
|
27.51
24.86 – 32.15
-17.7% YoY
|
37.64
31.97 – 42.02
+36.8% YoY
|
47.84
39.30 – 54.58
+27.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 77.6K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 34.4K | 0.48% |
| 3 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 6.2K | 0.22% |
| 4 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 18.5K | 0.22% |
| 5 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 10.0K | 0.22% |
| 6 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 4.4K | 0.22% |
| 7 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 1.9K | 0.24% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 1.9K | 0.24% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 506.89 | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 166.55 | 0.31% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sudhir Jairam Vaid | Executive Chairman & MD | 60M | male |
| Ankur Vaid | Joint MD, Chief Executive Officer & Executive Director | 33M | male |
| Raviraj Kariaas | Chief Financial Officer | 7M | male |
| Prakash Lalchand Sajnani | Assistant Vice President of Accounts & Finance | 4M | male |
| Paritosh Trivedi | Company Secretary, Compliance Officer & Nodal Officer | — | male |
| Manoj Kumar | Vice President of Formulation Division & Head of Valthera Unit-2 | — | male |
| Devang Bhatt | Vice President of Sales & Marketing and Head of Limbasi Plant-3 | — | male |
| Sundeep Bengani | General Manager, International Business Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CONCORDBIO.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
